The 10 Wall Street analysts covering Faeth Therapeutics, Inc. hold a median 12-month price target of $55 — +101.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 56 of 100 as at 1 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Faeth Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (93): The shares have been drifting up relative to others.
Volatility (11): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own Faeth Therapeutics, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on FTH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +101.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 July 2026 | Raymond James | Initiates | Outperform | $56 |
| 28 July 2026 | Oppenheimer | Initiates | Outperform | $60 |
| 20 July 2026 | Citizens | Initiates | Market Outperform | $51 |
| 20 July 2026 | Citizens | Initiates | Market Outperform | — |
| 16 July 2026 | BTIG | Reiterates | Buy | — |
| 16 July 2026 | BTIG | Reiterates | Buy | $55 |
| 26 June 2026 | Baird | Initiates | Outperform | $57 |
| 26 June 2026 | Baird | Initiates | Outperform | — |
| 22 June 2026 | HC Wainwright & Co. | Initiates | Buy | $60 |
| 22 June 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 15 June 2026 | BTIG | Reiterates | Buy | — |
| 11 June 2026 | BTIG | Initiates | Buy | — |
| 29 May 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 28 May 2026 | LUCID CAPITAL MARKETS | Initiates | Buy | — |
| 22 May 2026 | Citigroup | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 84% of US stocks
Cheaper than 93% of US stocks
Cheaper than 58% of US stocks
Higher than 35% of US stocks
Higher than 30% of US stocks
Higher than 12% of US stocks
Higher than 3% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FTH appears on the weeks it earns a place.
An analyst began coverage on Faeth Therapeutics on a bullish note, as highlighted among top analyst initiations for the day.
Why it matters — A FTH watcher would care because a new analyst initiating coverage with a bullish outlook can influence investor attention and market perception of the stock.
The 10 Wall Street analysts covering Faeth Therapeutics, Inc. have a median 12-month price target of $55, with estimates ranging from $50 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Faeth Therapeutics, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Faeth Therapeutics, Inc. 56 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Faeth Therapeutics, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (93 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +101.2% from the last close, and Ticker Nerd's factor model ranks Faeth Therapeutics, Inc. 56 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Faeth Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FTH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $50 to $60 over the next 12 months.
Faeth Therapeutics, Inc. returned +164.8% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on integrating tumor metabolism into modern oncology treatment.
The most recent item we track (Benzinga, 31 July 2026): "This Faeth Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday". An analyst began coverage on Faeth Therapeutics on a bullish note, as highlighted among top analyst initiations for the day.
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on integrating tumor metabolism into modern oncology treatment. The company develops multi-node therapies that target the PAM (PI3K/AKT/mTOR) signaling pathway, one of the most frequently altered oncogenic pathways in cancer, with the aim of blocking cancer growth signals while also managing the nutrient supply that fuels tumors. Its lead program, PIKTOR, is an all-oral investigational combination designed to achieve deeper pathway suppression with improved tolerability by inhibiting multiple nodes simultaneously. Faeth Therapeutics leverages a data-driven discovery platform that links tumor genotypes with specific therapeutic regimens and precision metabolic interventions, including nutrition-based strategies, to modulate cancer metabolism. Headquartered in San Francisco, California, and operating as a biotechnology research company, Faeth Therapeutics plays a specialized role in the oncology market by advancing metabolism-focused treatments for solid tumors within the broader biopharmaceutical and cancer therapeutics ecosystem.
CEO Mr. Anand Parikh Esq., J.D. · 29 employees · United States · https://www.faeththerapeutics.com